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BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality in developed countries. It is
known that early detection results in improved survival, and consequently there is a need for improved diagnostic tools in CRC. The
plasma level of soluble urokinase plasminogen activator receptor (suPAR) was proposed as a marker in CRC patients. This study was
undertaken to evaluate the individual molecular forms of suPAR as discriminators in a group of patients undergoing endoscopical
examination following symptoms related to colorectal cancer.
METHODS: In a case–control study comprising 308 patients undergoing endoscopical examination following CRC-related symptoms,
77 CRC patients with adenocarcinoma were age and gender matched to: 77 patients with adenomas; 77 with other non-malignant
findings, and 77 with no findings. The different uPAR forms were measured in citrate plasma collected before endoscopical
examination, using three different Time Resolved – Fluorescence Immuno Assays (TR-FIA’s).
RESULTS: All soluble uPAR forms were found to be significantly higher in cancer patients than in patients presenting with other non-
malignant findings; uPAR(I) P¼0.0006, suPAR(I–III) Po0.0001 and suPAR(I–III)þ(II–III) Po0.0001, whereas no significant
difference was found when performing similar comparisons for patients presenting with adenomas. The odds ratio (OR) for the
comparison of uPAR(I) in patients with CRC to subjects with other non-malignant findings was 3.44 (95% CI:1.86–6.37). CRC
patients had a mean elevated level of 20.9% (95% CI:10.2–32.6) for suPAR(I–III) and 18.5% (95% CI:9.0–28.8) for suPAR
(I–III)þ(II–III) compared with subjects with non-malignant findings.
CONCLUSIONS: The findings confirm reports on increased uPAR expression in cancer patients and in particular elevated levels of suPAR
in blood from CRC patients and indicate that suPAR levels in blood are increasing during carcinogenesis. Although none of the
measured uPAR forms were cancer specific, our findings suggest that uPAR expression could be useful in the early detection of CRC
when combined with other markers and clinical variables.
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Colorectal Cancer (CRC) is a leading cause of cancer with an
estimated individual lifetime risk of 5% in developed countries.
Worldwide CRC accounts for approximately 1 million new
cases per year, and in Europe CRC is the second most prevalent
cancer and the second most important in relation to cancer-
specific death (Parkin et al, 2005; Ferlay et al, 2007). Outcome in
CRC patients relates to the stage of disease at diagnosis, and
because more than 50% of patients are diagnosed at a late stage of
disease, there is a need for new diagnostic tools for early
detection of CRC (Weitz et al, 2005). According to The World
Health Organization conditions for early detection should be an
appropriate disease-control approach: (1) concerning a common
disease with serious morbidity and mortality; (2) potential
screening tests should be able to accurately detect early-stage
disease; (3) treatment after detection should be proven to
improve prognosis relative to usual diagnosis; and (4) evidence
should exist that the potential benefits outweigh the potential
harms and costs of screening (Winawer et al, 1990). In this respect
CRC has been proposed as an ideal screening object, but so far no
ideal screening method has been found. Presently the ‘golden
standard’ for screening of patients at risk of CRC is colonoscopy,
as the incidence of CRC in screening populations undergoing
colonoscopy has been shown to decrease (Winawer et al, 1993;
Levin et al, 2008). However, this procedure is time consuming,
expensive, inconvenient for the patient and includes a small risk of
perforation, and consequently colonoscopy is not ideal for primary
population-based screening. The Faecal Occult Blood Test (FOBT)
was proposed as a potential screening tool even though the
sensitivity and specificity of this test were shown to vary
considerably in different studies, additionally low compliance
impose problems for the use of FOBT in CRC population-based
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sscreening (Hewitson et al, 2006; Burch et al, 2007). The search for
molecular markers in blood has been promising and multiple
markers have been proposed, but limited reproducibility results in
bias emphasizing the need for studies designed for this purpose
(Ransohoff, 2007). No serological marker has yet been accepted for
use in early detection of CRC (Duffy et al, 2007), even though some
serological biomarkers, among these the urokinase receptor,
uPAR, have proven to be strong prognostic markers in CRC
(Stephens et al, 1999).
The plasminogen activation system (PA-system) is involved in
tissue remodelling processes, including tumour invasion and
metastasis (Werb, 1997; Irigoyen et al, 1999; Andreasen et al, 2000).
Components of this system including the urokinase plasminogen
activator (uPA), its receptor uPAR and the uPA inhibitor (PAI-1),
have been shown to be elevated in tumour tissue and blood from
cancer patients including patients with CRC (Ganesh et al, 1994, 1996;
Pedersen et al, 1994; Stephens et al,1 9 9 9 ;M u s t j o k iet al, 2000; Riisbro
et al, 2002; Hoyer-Hansen and Lund, 2007).
uPAR has a central function, because binding of the zymogen
pro-uPA initiates activation of cell surface bound plasminogen
leading to other proteolytic events in the extracellular matrix (Ellis
et al, 1989). UPAR(I–III) consists of three domains denoted
uPAR(I), uPAR(II) and uPAR(III) connected by two linker regions,
and the crystal structure has been solved (Llinas et al, 2005).
uPAR(III) is attached to cell membrane by a glycosyl–phospha-
tidyl–inositol (GPI) anchor(Ploug et al, 1991). Intact uPAR is
required for efficient binding of uPA (Hoyer-Hansen et al, 1997).
uPAR(I–III) can also be cleaved in the linker region between
domains I and II by uPA, liberating uPAR(I) and leaving the
cleaved form, uPAR(II–III) on the cell surface (Hoyer-Hansen
et al, 1992). uPA has been shown to cleave uPAR in vivo (Zhou
et al, 2000). uPAR is shed from the cell surface and soluble forms
of uPAR: suPAR(I–III), suPAR(II–III) and uPAR(I) have been
detected in various body fluids (Hoyer-Hansen and Lund, 2007).
Although the mechanism of uPAR shedding is not clarified,
evidence has been provided that the glycolipid (GPI) anchor can be
cleaved by endogenous cellular GPI-specific phospholipase D
(GPI–PLD) (Wilhelm et al, 1999). Although GPI-anchored
uPAR(I–III) is readily cleaved by uPA, suPAR(I–III) cannot be
cleaved by uPA in the linker region between domains I and II
(Hoyer-Hansen et al, 2001; Hoyer-Hansen and Lund, 2007).
Thus, uPAR(I) detected in blood results from cell surface
cleavage of uPAR(I–III) and suPAR(II–III) is in addition shed
from the cell surface.
In colon cancer uPAR is expressed by tumour-infiltrating
macrophages and fibroblasts and by a few cancer cells (Pyke
et al, 1994; Ohtani et al, 1995). Total levels of all uPAR forms in
tumour extracts and as before mentioned in blood have been
shown to correlate with poor prognosis in patients with colorectal
cancer (Ganesh et al, 1994; Stephens et al, 1999; Konno et al,
2001). We hypothesized that cleavage of uPAR is an indication of
an active plasminogen activation system and that the amounts of
the individual cleavage products would consequently be superior
to the total uPAR level as diagnostic markers of cancer. To
investigate this we employed immunoassays selectively quantifying
the individual uPAR forms (Piironen et al, 2004). Using these
assays we have previously shown that the serum level of uPAR(I)
enhances the discrimination of benign from malignant prostatic
disease (Piironen et al, 2006). In addition, uPAR(I) was found to be
a stronger prognostic marker than the total amount of uPAR in
non-small cell lung cancer (Almasi et al, 2005). In a recent study,
we also showed that suPAR(I) in blood enhances discrimination of
benign from malignant disease and uPAR(I) in blood predicts
survival in patients with ovarian cancer (Henic et al, 2008).
This case–control study was undertaken to evaluate the
potential discriminatory value of the plasma uPAR variants in
four diagnostic groups of patients undergoing endoscopical
examination following symptoms related to CRC.
SUBJECTS AND METHODS
Subjects
From October 2003 through December 2005, subjects were
included in a multi-centre cross sectional study conducted at six
Danish hospitals. Eligible for inclusion were patients (aged 18þ
years) undergoing endoscopical examination following symptoms
related to CRC and patients attending surveillance programs due
to Hereditary Colorectal Cancer (HNPCC and FAP). Subjects
previously diagnosed with CRC and subjects unable to give
informed consent were excluded from the study. The Regional
Ethical Committee approved the study. Following oral and written
consent according to the Helsinki II Declaration, 5165 individuals
were included consecutively – for details see (Nielsen et al, 2007).
Based on this study population a case–control study was designed
including 312 patients representing four diagnostic groups of
subjects. This study population was selected to test the diagnostic
potential of different promising serological markers in CRC.
Primarily, 78 subjects with pathologically verified colorectal
adenocarcinomas (25% RC, n¼20 and 75% CC, n¼58) were
selected at random. For each of these, a subject with pathologically
verified adenomatous changes was randomly selected matching for
age, gender and localisation of finding. Then subjects with other
(non-malignant) findings were randomly selected and matched as
described for the adenomas, and finally subjects were randomly
selected who had no findings at endoscopy and who reported no
co-morbidity. All pathological diagnoses were validated using the
Danish National Registry on Pathological Examinations (www.
patobank.dk). Patients who were diagnosed with cancer but did
not have the tumour removed were classified according to the
clinical information available, and as a result exact tumour staging
was not possible in all cases. Similarly for patients diagnosed with
adenomas, the type of adenoma was not specified in all cases,
either because of incompleteness of the pathological description
available or due to loss for specimen during the examination.
Previous cancer diagnoses were retrieved from the Danish Cancer
Registry, one subject had a previous CRC and was excluded from
the study together with three matched subjects, leaving a study
population of 308 subjects. Descriptive statistics for the matched
subjects are given in Table 1.
Sampling
Blood samples were collected before endoscopical examination in
all subjects, following a standard operating procedure (Nielsen
et al, 2007).
At sample collection subjects were non-fasting. Patients under-
going colonoscopy had completed a bowel preparation. Blood was
collected at moderate tourniquet pressure; in 4ml citrate-coated
tubes (Vacutainer Becton-Dickinson, Mountain View, CA, USA),
and spun for 10min at 2500g and 41C within 1h following
collection. Plasma was collected and samples were immediately
stored at  801C and were thawed and refrozen once before
analysis.
Immunoassay
Samples were analysed using three different Time Resolved
Fluorescence Immuno Assays (TR-FIAs). TR-FIA 1 measuring
full-length suPAR(I–III), TR-FIA 2 measuring full-length and
cleaved suPAR(I–III)þ(II–III), and TR-FIA 3 measuring liber-
ated domain I, uPAR(I). All samples were analysed in a 1:5
dilution. The assays and their validation in citrate plasma have
previously been described (Henic et al, 2008). In all three settings
samples were read in the Floustar Galaxy fluorometer with
excitation set at 405nm and emission read at 615nm with a
400ms delay and a 400ms acquisition window.
Intact and cleaved forms of the urokinase receptor
AF Lomholt et al
993
British Journal of Cancer (2009) 101(6), 992–997 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sStatistics
Descriptive statistics are presented by the median, minimum,
maximum or frequency if applicable. The Spearman’s rank
correlation was used as a measure of association. The statistical
analyses were based on a case–control design. For suPAR(I–III)
and suPAR(I–III)þ (II–III) a normal distribution was assumed
following log-transformation (natural). Domain I (uPAR(I)) was
treated as a binary variable using the limit of quantification of the
assay as the cut-point. Primarily a test for association between the
serological marker and CRC, adenoma, ONM findings and no
findings (hereafter denoted diagnosis groups) was carried out. The
analysis was done using a general linear model with diagnosis
group as the explanatory variable and the serological marker as the
dependent variable. For markers normally distributed on the log
scale, the link function used was the identity function and for
dichotomized serological markers, the logit was chosen as the link
function. The analysis used repeated measures with subject being
each case with corresponding samples. For each case, the
proportion of cancer patients with uPAR levels exceeding the
level found in the corresponding adenoma, ONM and no finding
was estimated with 95% CI.
Database management and statistical calculations were done
using SAS (v 9.1, SAS Institute, Cary, NC, USA). P-values below 5%
were considered significant.
RESULTS
Patient characteristics for the 77 matched subjects including age;
gender and localization of findings are given in Table 1. In Figure 1
plasma levels of the different uPAR forms are depicted for each
diagnostic group. All soluble uPAR forms were found to be
significantly higher in cancer patients than in patients presenting
with ONM findings; uPAR(I) P¼0.0006, suPAR(I–III) Po0.0001
and suPAR(I–III)þ(II–III) Po0.0001. Comparisons between the
group of patients presenting with adenomas and the remaining
diagnostic groups showed no significant difference.
Association between the different suPAR variants
To evaluate the association between the different suPAR variants
the Spearman’s rank coefficient was calculated. In all cases a
significant correlation between the different suPAR variants was
shown po0.0001 (data not shown). The weakest correlation was
found comparing uPAR(I) and suPAR(I–III) resulting in a 0.60
correlation coefficient (Po0.0001).
Discriminatory value of the different uPAR variants
Domain I; uPAR(I) uPAR(I) was treated as a binary variable with
the limit of quantification (LOQ¼20.19fmolml
 1) as the cut-
point. The resulting discrimination is shown in Table 2. Perform-
ing a general evaluation of the differences between the different
groups (type 3 hypothesis) a significant difference was found
(P¼0.008). A repeated measures analysis shows that in the cancer
group there are significantly more cases with uPAR(I) levels above
the quantification limit than in the group with ONM findings
Table 2 uPAR(I) treated as a binary variable with cut-point at the limit of
quantification or the 3rd quartile
Diagnostic group
Limit of quantification +
uPAR(I), n (%)
43rd quartile +
uPAR(I), n (%)
CRC 46 (59.7) 25 (32.5)
Adenoma 36 (46.8) 18 (23.4)
Other non-
malignant finding
28 (36.4) 12 (15.6)
No finding 38 (49.4) 22 (28.6)
The table shows the proportion of subjects with detectable uPAR(I) in each diagnosis
group (n¼77).
Table 1 Subject characteristics for each case/controls with 77 individuals
in each group
Subjects, n (%)
Gender
Female 37 (48)
Male 40 (52)
Age group
40+ 3 (4)
50+ 10 (13)
60+ 17 (22)
70+ 26 (34)
80+ 21 (27)
Localisation
Right colon 23 (30)
Left colon 34 (44)
Rectum 20 (26)
Cancer stage
I 9 (12)
II 32 (42)
III 16 (21)
IV 15 (19)
not specified 5 (6)
Adenomas
Tubular 45 (58)
Tubulovillous 16 (21)
Villous 1 (1)
Serrat 1 (1)
Not specified 14 (18)
Size
o1cm 41 (53)
41cm 33 (43)
Not specified 3 (4)
Other non-malignant finding
Diverticulosis 72 (94)
Haemorrhoids 4 (5)
Inflammatory bowel disease 1 (1)
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Figure 1 Box plot showing the distribution of the different plasma uPAR
forms in the four different diagnostic groups.
Intact and cleaved forms of the urokinase receptor
AF Lomholt et al
994
British Journal of Cancer (2009) 101(6), 992–997 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(P¼0.009), whereas all other comparisons are non-significant.
Dichotomizing the data at the 3rd quartile (31.23fmolml
 1) did
not result in an improved discrimination (Table 2). Odds ratios
were calculated to evaluate the probability of uPAR(I) being
elevated in one diagnostic group compared with another.
Significant ORs were found when comparing the ONM finding
group to the CRC group (Table 3).
suPAR (I–III) Intact suPAR (suPAR(I–III)) was treated as a
continuous variable on the log scale, and the discriminatory value
was evaluated comparing mean levels for the different diagnostic
groups given as the relative difference (Table 4). The type
3-hypothesis test was significant (P¼0.002). When comparing
the CRC group to ONM and ‘no findings’ group’s significant
relative differences in mean suPAR(I-III) levels were found (20.9%
(95% CI:10.2–32.6), Po0.0001 and 17.0% (95% CI:5.5–29.7),
P¼0.003, respectively). Comparison of the adenoma and ONM
finding groups showed a relative difference of 9.9% ((95% CI: 0.1–
21.0), P¼0.052) All other comparisons were insignificant. Pooling
the non-CRC groups and testing for a difference between CRC and
this group showed a significant difference (P¼0.002).
suPAR(I–III)þ(II–III) Intact and cleaved suPAR (suPAR(I–
III)þ(II–III)) was treated as a continuous variable on the log
scale, and the discriminatory value was evaluated comparing mean
levels for the different diagnostic groups (Table 4). The type 3
hypothesis was significant (P¼0.004). For suPAR(I–III)þ(II–III)
a significant difference was found comparing suPAR(I–III)þ
(II–III) levels in the CRC group to the levels in the ONM finding
group (18.5% (95% CI:9.0–28.8), Po0.0001). The relative
difference between the CRC patients and subjects with no findings
was 11.3% (95% CI: 0.1–24.0, P¼0.052), for subjects with
adenomas compared to those with ONM finding the difference
was 8.9% (95% CI: 0.8–19.5, P¼0.072). All other comparisons
were insignificant. Pooling the groups presenting no CRC and
testing for a difference between the CRC group and this group
showed a significant difference (P¼0.007).
Proportional analyses of all uPAR variants The proportion of
patients presenting higher uPAR values than patients in the other
diagnosis groups was analysed for each case, and for the M0 (¼no
distant metastasis diagnosed) CRC patients, respectively. Results
are given in Table 5.
DISCUSSION
In this case–control study, plasma levels of the different uPAR
variants were shown to increase with severity of each diagnostic
group. For all three markers significant higher levels were seen in
the CRC group compared with the uPAR levels in the other three
diagnostic groups, suggesting that the markers used in this study
may be potential discriminators in the early detection of colorectal
cancer. Even though none of the markers were cancer specific the
suPAR variants should not be excluded as potential tools in the
detection and classification of CRC patients. Previous studies have
shown diagnostic value of uPAR variants when combined with
other serological markers in both ovarian and prostate cancer
(Piironen et al, 2006; Henic et al, 2008).
In this study the number of patients with detectable levels of
uPAR(I) was shown to be significantly lower in the diagnostic
group ‘ONM findings’ compared with the CRC and adenoma
groups. For the levels of suPAR(I–III)þ(II–III) significant
differences were only seen when comparing the groups CRC and
‘ONM findings’. Therefore uPAR(I), when compared with other
soluble uPAR forms, may be superior as a diagnostic marker in
CRC. When this was analysed by a proportional analysis of each
case compared with matched patients from the other diagnosis
groups (Table 5), uPAR(I) were not superior to the two other
uPAR variants studied. However, there are strong indications that
the blood level of uPAR(I) reflects the activity of uPA (Zhou et al,
2000). Thus high levels are indicative of high uPA activity, leading
to plasmin formation and breakdown of the extracellular matrix,
which is a prerequisite for cancer invasion (Dano et al, 2005).
Notably levels of uPAR(I) have previously been shown to be of
interest both in cancer detection and as a prognostic marker
(Almasi et al, 2005; Piironen et al, 2006; Henic et al, 2008).
In all analyses of the different uPAR forms, the CRC group
presented significantly higher values than the remaining groups.
This observation supports the hypothesis that suPAR levels in
blood are increasing during carcinogenesis (Piironen et al, 2006;
Henic et al, 2008) and despite the insignificant differences between
Table 3 The odds ratios (OR) for elevated uPAR(I) comparing
diagnostic groups.(ONM¼other non-malignant)
Groups
Odds ratio and
(95% confidence limits) P-value
ONM finding vs no finding 0.50 (0.25–0.99) 0.047
Adenoma vs no finding 1.18 (0.62–2.23) 0.611
Adenoma vs ONM finding 2.38 (1.27–4.47) 0.007
CRC vs adenoma 1.45 (0.79–2.63) 0.235
CRC vs no finding 1.71 (0.91–3.18) 0.093
CRC vs ONM finding 3.44 (1.86–6.37) o0.0001
Table 4 Relative mean difference (%) between the diagnostic groups for
intact suPAR and intact+cleaved suPAR
Marker Groups
Relative mean
difference and
(95% confidence
limits in %) P-value
suPAR(I–III) Non-malignant vs No  3.3 ( 13.3–5.8) 0.488
P¼0.002
a Adenoma vs no finding 6.4 ( 3.4–17.2) 0.208
Adenoma vs ONM finding 9.9 ( 0.1–21.0) 0.052
CRC vs adenoma 9.0 ( 1.5–18.5) 0.089
CRC vs no finding 17.0 (5.5–29.7) 0.003
CRC vs ONM finding 20.9 (10.2–32.6) o0.0001
suPAR(I–III)+(II–III) Non-malignant vs No  6.5 ( 17.0–3.1) 0.190
P¼0.004
a Adenoma vs no finding 2.3 ( 7.2–12.7) 0.653
Adenoma vs ONM finding 8.9 ( 0.8–19.5) 0.072
CRC vs adenoma 8.1 ( 1.9–17.2) 0.110
CRC vs no finding 11.3 ( 0.1–24.0) 0.052
CRC vs ONM finding 18.5 (9.0–28.8) o0.0001
aResults of type III hypothesis tests (ONM¼other non-malignant).
Table 5 Showing the proportion of cancer patients with uPAR levels
exceeding the level found in the corresponding adenoma, ONM and no
finding was estimated with 95% CI
Subset
Adenoma
(95% CI)
Other
(95% CI)
None
(95% CI)
suPAR( I–III)+(II–III) All 64 (53–74) 70 (60–80) 66 (56–77)
M0 59 (44–73) 67 (54–80) 61 (48–75)
suPAR(I–III) All 55 (43–66) 70 (60–80) 64 (53–74)
M0 51 (37–65) 67 (54–80) 61 (48–75)
uPAR(I)
a All 61 (49–73) 67 (55–80) 60 (48–72)
M0 54 (38–70) 68 (49–83) 59 (44–75)
M0¼analyses restricted to the group of patients presenting no distant metastases
(n¼49).
aTies excluded.
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sthe adenoma group and ‘ONM/no findings’ groups the hypothesis
was supported by a ‘trend’ going towards the level of significance
when comparing these groups (see Table 4). As shown in Table 1
all diagnoses in the adenoma group could not be certified
pathologically, a fact that may bias our findings. In addition, it
is well established that some adenomas have higher risk of
transforming into carcinomas than others (Bond, 2003). Owing to
data limitations differences in uPAR levels were not studied
according to adenoma type or size, variables that are indeed of
great interest when studying potential screening markers in CRC.
For all markers the most significant differences between groups
were found when comparing the diagnostic groups: CRC and
‘ONM finding’. Initially the group of ‘no finding’, characterized by
having no reported co-morbidity and no findings at endoscopical
examination, were expected to present with the lowest levels of the
different uPAR forms and hence the most significant differences
compared with CRC. When interpreting the results of this study, it
should be noted that all included subjects were symptomatic and
when looking at the actual mean values for the two groups: no
findings and ‘ONM’ findings they were only slightly different
 3.3% for suPAR (I–III) and  6.5% for suPAR (I–III)þ(II–III).
The diagnostic group of ‘ONM finding’ appeared to be very
homogeneous and – with one exception – only included subjects
presenting benign lesions of the bowel wall (diverticulosis and
haemorrhoids). suPAR has been reported to be elevated in
different cancers, but whether suPAR is elevated in other systemic
diseases is not well described. Total suPAR has been shown to be
elevated in patients with infectious and inflammatory diseases;
hence suPAR levels may be elevated because of co-morbidity.
Patients could have systemic disease at the time of the examination
that were not registered and hence present increased levels
of uPAR.
All soluble uPAR forms were shown to be markers of interest in
the detection of CRC despite the fact that they were not cancer
specific. These findings lead to the hypothesis that including these
markers in a multi-marker profile could be beneficial in the
detection and classification of CRC when combined with other
markers and clinical variables, as previously shown in prostate and
ovarian cancer.
A sufficiently powered study including other variables that may
influence the uPAR levels (co-morbidity, life style variables) could
be conducted measuring uPAR levels in the original study
population of more than 5000 individuals. This would allow for
an evaluation of the possibility of identifying individuals with a
high risk for CRC adjusted for relevant clinical variables and to
evaluate uPAR levels in association with other serological
biomarkers such as carcinoembryonic antigen and plasma tissue
inhibitor of metalloproteinases-1 (Nielsen et al, 2007).
ACKNOWLEDGEMENTS
The excellent technical assistance of Ruth Petersson is gratefully
acknowledged. The Danish–Australian Endoscopy Study Group
on Colorectal Cancer Detection is thanked for providing the
samples and clinical data. The study was supported by: EU
contract LSHC-CT-2003-503297, The Kornerup Fund, The Aase
and Ejnar Danielsen Fund, The Aage and Johanne Louis-Hansen
Fund, The Walter and O. Kristiane Christensen Fund, The Sophus
and Astrid Jacobsen Fund, The Arvid Nilsson Fund, The Glunz and
Jensen Fund, The Friedrich and Else Boehm Fund, The Agnes and
Poul Friis Fund, The Eva and Henry Fraenkel Fund, The Hartmann
Bros. Fund, The Willy and Ingeborg Reinhard Fund, The Katrine
and Vigo Skovgaard Fund, The Oda and Hans Svenningsen Fund,
The Einar Willumsen Fund, and The Danish Cancer Society (Hans
Jørgen Nielsen is Danish Cancer Society Professor of Surgical
Oncology).
REFERENCES
Almasi CE, Hoyer-Hansen G, Christensen IJ, Dano K, Pappot H (2005)
Prognostic impact of liberated domain I of the urokinase plasminogen
activator receptor in squamous cell lung cancer tissue. Lung Cancer 48:
349–355
Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation
system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:
25–40
Bond JH (2003) Colon polyps and cancer. Endoscopy 35: 27–35
Burch JA, Soares-Weiser K, St John DJ, Duffy S, Smith S, Kleijnen J,
Westwood M (2007) Diagnostic accuracy of faecal occult blood tests used
in screening for colorectal cancer: a systematic review. J Med Screen 14:
132–137
Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M,
Romer J (2005) Plasminogen activation and cancer. Thromb Haemost 93:
676–681
Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E, Klapdor R,
Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers
in colorectal cancer: European Group on Tumour Markers (EGTM)
guidelines for clinical use. Eur J Cancer 43: 1348–1360
Ellis V, Scully MF, Kakkar VV (1989) Plasminogen activation initiated by
single-chain urokinase-type plasminogen activator. Potentiation by U937
monocytes. J Biol Chem 264: 2185–2188
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007)
Estimates of the cancer incidence and mortality in Europe in 2006. Ann
Oncol 18: 581–592
Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K,
van d V, Verheijen JH, Lamers CB, Verspaget HW (1996) Prognostic
value of the plasminogen activation system in patients with gastric
carcinoma. Cancer 77: 1035–1043
Ganesh SJ, Sier C, Heerding M, Griffioen G, Lamers C, Verspaget H (1994)
Urokinase receptor and colorectal cancer survival. The Lancet 344:
401–402
Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G (2008)
Cleaved forms of the urokinase plasminogen activator receptor in plasma
have diagnostic potential and predict postoperative survival in patients
with ovarian cancer. Clin Cancer Res 14: 5785–5793
Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2006) Screening for
colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane
Database Syst Rev, Issue 4: Art. No: CD001216
Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The
intact urokinase receptor is required for efficient vitronectin binding:
receptor cleavage prevents ligand interaction. FEBS Lett 420: 79–85
Hoyer-Hansen G, Lund IK (2007) Urokinase receptor variants in tissue and
body fluids. Adv Clin Chem 44: 65–102
Hoyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Dano K, Behrendt N
(2001) Urokinase-catalysed cleavage of the urokinase receptor requires
an intact glycolipid anchor. Biochem J 358: 673–679
Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis
V, Dano K (1992) Urokinase plasminogen activator cleaves its cell
surface receptor releasing the ligand-binding domain. J Biol Chem 267:
18224–18229
Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y (1999)
The plasminogen activator system: biology and regulation. Cell Mol Life
Sci 56: 104–132
Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, Kamiya K,
Tanaka T, Suzuki S, Nakamura S, Urano T (2001) Urokinase receptor
and vascular endothelial growth factor are synergistically associated with
the liver metastasis of colorectal cancer. Jpn J Cancer Res 92: 516–523
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS,
Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson
A, Winawer SJ, for the American Cancer Society Colorectal Cancer
Advisory Group tUM-STFatACoRCCC (2008) Screening and Surveillance
for the Early Detection of Colorectal Cancer and Adenomatous Polyps,
2008: A Joint Guideline from the American Cancer Society, the US
Multi-Society Task Force on Colorectal Cancer, and the American
College of Radiology. CA Cancer J Clin 58: 130–160
Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA,
Menez A (2005) Crystal structure of the human urokinase plasminogen
Intact and cleaved forms of the urokinase receptor
AF Lomholt et al
996
British Journal of Cancer (2009) 101(6), 992–997 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sactivator receptor bound to an antagonist peptide. EMBO J 24:
1655–1663
Mustjoki S, Sidenius N, Sier CFM, Blasi F, Elonen E, Alitalo R, Vaheri A
(2000) Soluble urokinase receptor levels correlate with number of
circulating tumor cells in acute myeloid leukemia and decrease rapidly
during chemotherapy. Cancer Res 60: 7126–7132
Nielsen HJ, Brunner N, Frederiksen CB, Lomholt AF, King D, Jørgensen LN,
Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurgberg S, Christensen IJ
(2007) Plasma tissue inhibitor of metalloproteinases-1(TIMP-1): A novel
biological marker in the detection of primary colorectal cancer. Protocol
outlines of the Danish–Australian endoscopy study group on colorectal
cancer detection. Scand J Gastroenterol 43(2): 242–248
Ohtani H, Pyke C, Dano K, Nagura H (1995) Expression of urokinase
receptor in various stromal-cell populations in human colon cancer:
immunoelectron microscopical analysis. Int J Cancer 62: 691–696
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer Statistics, 2002.
CA Cancer J Clin 55: 74–108
Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH,
Dano K, Grondahl-Hansen J (1994) Prognostic impact of urokinase,
urokinase receptor, and type 1 plasminogen activator inhibitor in
squamous and large cell lung cancer tissue. Cancer Res 54: 4671–4675
Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano
K, Hoyer-Hansen G, Lilja H (2006) Enhanced discrimination of benign
from malignant prostatic disease by selective measurements of cleaved
forms of urokinase receptor in serum. Clin Chem 52: 838–844
Piironen T, Laursen B, Pass J, List K, Gardsvoll H, Ploug M, Dano K, Hoyer-
Hansen G (2004) Specific immunoassays for detection of intact and
cleaved forms of the urokinase receptor. Clin Chem 50: 2059–2068
Ploug M, Behrendt N, Lober D, Dano K (1991) Protein structure and
membrane anchorage of the cellular receptor for urokinase-type
plasminogen activator. Semin Thromb Hemost 17: 183–193
Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K (1994)
Immunohistochemical detection of the receptor for urokinase
plasminogen activator in human colon cancer. Histopathology 24:
131–138
Ransohoff DF (2007) How to improve reliability and efficiency of research
about molecular markers: roles of phases, guidelines, and study design.
J Clin Epidemiol 60: 1205–1219
Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW,
Han C, Hoyer-Hansen G, Smith K, Brunner N, Harris AL (2002)
Prognostic significance of soluble urokinase plasminogen activator
receptor in serum and cytosol of tumor tissue from patients with
primary breast cancer. Clin Cancer Res 8: 1132–1141
Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S,
Dano K, Brunner N (1999) Plasma urokinase receptor levels in patients
with colorectal cancer: relationship to Prognosis. J Natl Cancer Inst 91:
869–874
Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005)
Colorectal cancer. Lancet 365: 153–165
Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology.
Cell 91: 439–442
Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, Schmitt M,
Rifkin DB, Wilson EL, Graeff H, Brunner G (1999) Cellular glycosylpho-
sphatidylinositol-specific phospholipase D regulates urokinase receptor
shedding and cell surface expression. J Cell Physiol 180: 225–235
Winawer SJ, St JJ, Bond J, Hardcastle JD, Kronborg O, Flehinger B,
Schottenfeld D, Blinov NN (1990) Screening of average-risk individuals
for colorectal cancer. WHO collaborating centre for the prevention of
colorectal cancer. Bull World Health Organ 68: 505–513
Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS,
Waye JD, Schapiro M, Bond JH, Panish JF (1993) Prevention of colorectal
cancer by colonoscopic polypectomy. The National Polyp Study Work-
group. N Engl J Med 329: 1977–1981
Zhou HM, Nichols A, Meda P, Vassalli JD (2000) Urokinase-type
plasminogen activator and its receptor synergize to promote pathogenic
proteolysis. EMBO J 19: 4817–4826
Intact and cleaved forms of the urokinase receptor
AF Lomholt et al
997
British Journal of Cancer (2009) 101(6), 992–997 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s